Outset Medical, Inc. (OM) Stock

Outset Medical, Inc. (OM) is a Healthcare stock trading at $4.29 (as of 2026-08-20), with a market capitalization of $80.55M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Outset Medical, Inc. develops a hemodialysis system, including the Tablo Hemodialysis System with a compact console, integrated water purification, on-demand dialysate production, and software and connectivity features. It supports dialysis care in acute and home settings.

Understand Outset Medical, Inc.: how it makes money

Outset Medical makes the Tablo hemodialysis system (a compact console with integrated water purification, on-demand dialysate production, and software connectivity) and earns money from selling its system and related product revenue, treatment revenue, and service and other revenue tied to ongoing care using the Tablo platform.

The company’s profit engine is scaling the installed base of Tablo consoles so that ongoing dialysis use supports recurring revenue from Tableau consumables and service, alongside product and treatment-related revenue.

Revenue by segment (latest quarter)
Product$0.0B
Treatment$0.0B

Business quality (Weak): Latest-quarter profitability was weak (operating margin -60.7%), and the data shows revenue near 0.0B with a positive gross margin (43.4%), indicating heavy operating expense relative to current revenue.

Bull case

  • Home dialysis retention at 90 days is 90%: That supports the idea of repeat use in home settings, which can help underpin recurring revenue tied to ongoing dialysis care.
  • Tablo is designed for both acute and home dialysis settings: This can diversify where patients receive treatment, and it aligns with the platform revenue mix that includes consumables and service.

Bear case

  • Operating margin was -60.7% in the latest quarter: If revenue does not grow fast enough to absorb operating costs, losses can persist even with a positive gross margin.
  • Revenue is extremely low in the latest-quarter snapshot (reported revenue is 0.0B): Small changes in treatment volumes or installed-base utilization could create large swings in results and make near-term performance harder to interpret.
Valuation — source: SEC EDGAR (first-party)
Price$4.29
Market Cap$80.55M
Price / Book0.84
Price / Sales0.69
FCF Yield-106.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$119.48M
Net Margin-68.3%
Revenue Growth (YoY)5.1%
EPS Growth (YoY)118.3%
FCF Growth (YoY)-59.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-5.27 (distress)
Piotroski F-Score7/9 (strong)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($10.53M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOLeslie L. Trigg
Employees354
CountryUS
IPO Date2020-09-15

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Stereotaxis, Inc. (STXS)
  • FONAR Corporation (FONR)
  • Vivani Medical, Inc. (VANI)
  • Streamex Corp. (STEX)
  • electroCore, Inc. (ECOR)
  • Hyperfine, Inc. (HYPR)
  • NeurAxis, Inc. (NRXS)
  • Precision Optics Corporation, Inc. (POCI)
OM earnings history · OM institutional & insider holders · OM KPIs & operating metrics · OM financials · OM investor presentations & press releases · OM SEC filings · OM peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.